Predictmedix Stock Price, News & Analysis

Predictmedix AI (OTC:PMEDF) has launched its Clinical-Trial AI Platform, an advanced solution targeting the $70 billion clinical trials market. The platform leverages patented technology and data from SmartHealth AI Stations to optimize clinical trial planning and execution.

The platform features an adaptive simulation engine, patient-site optimization, cost modeling, and interactive dashboards. Built on validated data streams from over 500,000 SmartHealth scans with approximately 95% accuracy for vital-sign detection, the system provides real-time analytics and continuous intelligence for pharmaceutical sponsors and CROs.

The company is now preparing to offer private demonstrations and explore paid pilot programs with potential clients in the pharmaceutical industry.

Predictmedix AI (OTC: PMEDF) announced its participation in the upcoming 25th MK Investment Conference in Munich, Germany on October 1, 2025. The company's COO and Co-founder, Dr. Rahul Kushwah, will present their AI-powered health and safety technology solutions to a diverse investor audience.

The conference, hosted by Michael Kott and CM-Equity AG, focuses on AI, Longevity, Tech, and ESG sectors. Dr. Kushwah will showcase Predictmedix's proprietary AI technologies designed for health management, clinical trials, and screening applications, highlighting the company's growth vision and recent achievements.

Predictmedix AI (OTC: PMEDF) has unveiled a strategic expansion plan to transform from a single-product health screening company into a diversified AI health-technology enterprise. The company is developing three key growth platforms: a Clinical-Trial AI Platform targeting a $123.5B market by 2030, SmartHealth AI Stations with 95% accuracy in health screening, and a Consumer Vital-Scanning Mobile Application.

The company's strategy focuses on generating recurring revenue through SaaS subscriptions, Screening-as-a-Service, and consumer subscriptions. Their technology is backed by proprietary AI algorithms and targets the global AI healthcare market, projected to reach $187.7B by 2030 with a 38.6% CAGR from 2025-2030.

Predictmedix AI (OTC: PMEDF) announced its expansion into mobile diagnostics with a new AI-powered diabetes screening platform, initially targeting the Indian market. The platform enables non-invasive diabetic screening through smartphones, leveraging facial and biometric analysis technology.

The solution aims to address India's growing diabetes epidemic, where over 100 million people have diabetes and projections indicate nearly 1 in 3 adults will be diabetic or prediabetic by 2045. The platform features instant diabetic risk scoring, multilingual support, and secure data handling compliant with India's DPDP Act.

With India's smartphone user base exceeding 1.1 billion, the company plans to generate recurring revenue through both direct-to-consumer and B2B channels, with potential for global scalability.

Predictmedix AI (PMEDF) has formed a strategic alliance with Pacific Mechatronics to deploy its AI-powered Smart Health Stations across the Asia-Pacific defence sector. The partnership targets key markets including Singapore, Indonesia, Malaysia, the Philippines, and Vietnam.

The Smart Health AI Stations provide automated, contactless health screening using AI and multispectral imaging to detect fatigue, infectious diseases, cognitive impairment, and mental health anomalies. Pacific Mechatronics will lead deployment, integration, and support of these systems at border control zones, military installations, naval docks, and air command units.

The collaboration provides Predictmedix with direct access to defence ministries and aerospace buyers, enabling subscription-based revenue through licenses, maintenance, and upgrades. This expansion represents a parallel growth track alongside the company's North American operations.

Predictmedix AI (PMEDF) announces its participation in an exclusive European investor roadshow across three cities from May 17-21, 2025. The company will be showcasing its AI-driven health and safety solutions in Budapest (May 17), Zagreb (May 19), and Belgrade (May 21).

The roadshow follows recent investments from German family offices and aims to expand the company's European shareholder base. Predictmedix will highlight its Smarthealth AI stations, focusing on workplace safety, healthcare, and public event screening applications.

Additionally, the company has issued 850,000 common shares to a senior technology consultant and settled a debt of $64,806.45 through the issuance of 1,150,000 additional common shares, both subject to a four-month hold period.

Predictmedix AI (OTC: PMEDF) positions its Smart Health AI Stations as a strategic alternative following FDA's decision to phase out mandatory animal testing in drug development. The company's technology offers non-invasive, human-centric solutions for preclinical and clinical evaluations.

The AI-powered stations, which have conducted over 500,000 scans with up to 95% accuracy in vital sign detection, monitor various health indicators including vitals, impairment, fatigue, and infection markers. The technology provides real-time physiological and cognitive assessment through advanced algorithms.

The platform analyzes human biomarkers to predict physiological responses, offering direct human-relevant data instead of relying on animal models. Key features include AI-driven real-time assessments, scalable deployment options, contactless monitoring, and compliance with data privacy standards.

Predictmedix AI (CSE: PMED, OTC: PMEDF) has achieved a significant milestone with its Smart Health AI Stations completing over 500,000 individual scans. The company's non-invasive, AI-powered screening tools integrate advanced computer vision with adaptive machine learning to detect health risks including infectious disease symptoms, mental health indicators, and impairment in real-time.

The technology offers privacy-focused health insights and features rapid vitals screening and impairment detection capabilities. Dr. Rahul Kushwah, Chief Operating Officer, emphasized that the milestone demonstrates the trust earned and lives protected through their solution. The system's algorithms improve with each scan, enabling faster and more reliable interventions.

The company's Smart Health AI Stations are designed for deployment across healthcare, corporate, and public sectors, with expanding capabilities in mental health assessment, including detection of stress and fatigue. Predictmedix AI plans to strengthen industry partnerships and explore new opportunities in telemedicine and personalized analytics.

Predictmedix AI (CSE: PMED, OTC: PMEDF) has successfully closed the third and final tranche of its non-brokered private placement, raising $100,000 CAD. The placement saw strong insider participation, with $90,000 subscribed by insiders Sheldon Kales and Dr. Rahul Kushwah ($45,000 each).

The company issued 5,000,000 units at $0.02 per unit, with each unit comprising one common share and one purchase warrant. Warrants are exercisable at $0.05 per share for 24 months, with an acceleration clause if share prices exceed $0.10 for ten consecutive trading days.

Additionally, Predictmedix has begun fabrication of fifteen Smart Health AI Stations for strategic deployment, primarily targeting the United States market. The proceeds will support market expansion, with a focus on U.S. enterprise and government sectors.